Comparison of antiemetic effectiveness and safety of palonosetron and dexamethasone with palonosetron, dexamethasone and aprepitant in patients with lung cancer receiving combination therapy with carboplatin: A phase II randomized study

Comparison of antiemetic effectiveness and safety of palonosetron and dexamethasone with palonosetron, dexamethasone and aprepitant in patients with lung cancer receiving combination therapy with carboplatin: A phase II randomized study - Comparison of effectiveness of palonosetron and dexamethasone with palonosetron, dexamethasone and aprepitant in patients with lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010056

Enrollment

Registered

2013-03-10

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Patients received dexamethasone and palonosetron, and then received carboplatin. Patients received dexamethasone, palonosetron and aprepitant, and then received carboplatin.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced, metastatic or recurrent NSCLC Adequate function of the bone marrow, liver and kidney. PS(ECOG) 0-2

Exclusion criteria

Exclusion criteria: Patients with severe complications. Patients with brain metastasis. Patients with convulsive disorders requiring treatment. Patients with pleural effusion or ascites requiring treatment. Patients with gastrointestinal obstruction. Patients with drug sensitivities. Patients received antiemetic therapy as below, in the 24 hours before chemotherapy. 5HT3 receptor antagonist, NK1 receptor antagonist, adrenocortical steroid, antidopaminergic agent, phenothiazine derivative, antihistamine, benzodiazepine compound. Pregnant female, nursing mom.

Design outcomes

Primary

Measure	Time frame
Antiemetic effect	—

Countries

Japan

Contacts

Public ContactHideki Kusagaya

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026